Blonder Tongue Laboratories, Inc.
OLD BRIDGE, NJ / ACCESSWIRE / August 12, 2021 / Blonder Tongue Laboratories, Inc. (NYSE American:BDR) announced its sales and results for the second quarter and six months ended June 30, 2021.
Blonder Tongue Laboratories, Inc. net sales increased $507,000 or 13.2% to $4,338,000 for the second quarter of 2021 from $3,831,000 for the comparable period in 2020. Net income for the three months ended June 30, 2021, was $1,626,000 or $0.11 per diluted share, compared to a net loss of $(1,194,000) or $(0.12) per diluted share for the comparable period in 2020.
Commenting on the second quarter results, Ted Grauch, Blonder Tongue Laboratories' President and CEO noted, "In Q2 the Company saw several elements of our long-term strategy begin to come together yielding a positive first half in terms of income and net cash provided by operating activities. Our continued multi-year R&D investment in cutting edge digital IP and OTT video products led to significant year on year growth in our Clearview transcoder and NXG IP video processing product lines, helped by new customer wins by both product lines this year. Our expanded network of channel partners and direct service operator customers resulted in broader sources of revenue over the first half that we expect will continue for the foreseeable future. Also helping us along has been a continued steady improvement in the telecommunications and video service provider technology marketplace during the first half compared with the first 9 months of the pandemic in 2020. Our CPE programs are showing a planned reduction in revenue, as we transform those products and associated customer base into a service and fulfillment model. We will be transitioning a majority of future CPE COGS onto our product partners with a goal of greatly increasing the margins and cash-efficiency of those products going forward. Although the hospitality industry has been improving the last few months, it has lagged the recovery of the telecommunications sectors and so we will be working to improve our DOCSIS product line performance in the second half of the year to the extent allowed by hospitality market capital investment improvements. Finally, we are already working hard in the second half with a goal to keep up the momentum created in first half of 2021; expanding our broadband, ISP data delivery and ATSC off-air video related product lines, as well as bringing new technology to modernize a selection of Blonder Tongue headend and central office distribution products, already well-known for decades-long reliability in the field."
The increase in sales for the second quarter is primarily attributable to an increase in sales of video transcoder products, NXG IP video signal processing products and digital video headend products, offset by a decrease in sales of DOCSIS data products and CPE products. Sales of transcoder products were $1,337,000 and $279,000, NXG products were $470,000 and $285,000, digital video headend products were $968,000 and $745,000, DOCSIS data products were $327,000 and $701,000, and CPE products were $288,000 and $1,026,000 in the second three months of 2021 and 2020, respectively.
For the six months ended June 30, 2021, net sales decreased $292,000 or 3.7% to $7,589,000 in 2021 from $7,881,000 for the comparable period in 2020. Net income for the six months ended June 30, 2021, was $1,212,000 or $0.08 per diluted share, compared to a net loss of $(3,274,000) or $(0.34) per diluted share for the comparable period in 2020. Net cash provided by operating activities was $126,000 for the first six months of 2021, compared to net cash used in operating activities of $(2,029,000) for the comparable period of 2020.
The decrease in sales for the six months is primarily attributable to a decrease in sales of DOCSIS data products, digital video headend products, HFC distribution products and CPE products, offset by an increase in sales of transcoder products and NXG products. Sales of DOCSIS data products were $355,000 and $1,572,000, digital video headend products were $1,511,000 and $1,802,000, HFC distribution products were $923,000 and $1,170,000, CPE products were $983,000 and $1,672,000, transcoder products were $2,073,000 and $394,000 and NXG products were $891,000 and $481,000 in the first six months of 2021 and 2020, respectively.
The Company expects bookings of transcoder products to remain healthy as market exposure to, and acceptance of those products continues. The Company expects sales of CPE products to continue to trend lower than in prior periods as the Company, consistent with its business plan, transitions those products into a higher margin but lower revenue services, fulfillment, and support business model, and works to promote an expanded array of distribution, content delivery and processing technologies to those service provider customers.
The Company's primary sources of liquidity have been its existing cash balances, cash generated from operations and amounts available under the MidCap Facility. At June 30, 2021, the Company had $487,000 available under the MidCap Facility.
As disclosed in the Company's 2020 Annual Report on Form 10-K, last year the Company experienced a decline in sales, a reduction in working capital, a loss from operations and net cash used in operating activities, in conjunction with liquidity constraints. These factors raised substantial doubt about the Company's ability to continue as a going concern. The above factors still exist. Accordingly, there still exists substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Conference Call Reminder
Details of the live teleconference :
Date: Thursday, August 12, 2021
Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)
Investor Dial-in (US & Canada Toll-Free): 888-506-0062
International: 973-528-0011
Entry Code: 705019
The audio replay will be available under Investor Related Information on the Blonder Tongue Investor Relations webpage.
About Blonder Tongue
Blonder Tongue Laboratories, Inc. is the oldest designer and manufacturer of telecommunications and cable television video transmission technology in the USA. The majority of our products continue to be designed and built in our state-of-the-art New Jersey facility, which has been the Company's home for more than 50 years. Blonder Tongue Labs offers U.S.-based engineering and manufacturing excellence with an industry reputation for delivering ultra-high reliability products. As a leader in cable television system design, the Company provides service operators and systems integrators with comprehensive solutions for the management and distribution of digital video, IPTV and high-speed data services, as well as RF broadband distribution over fiber, IP, and Coax networks for homes and businesses. Additional information on the Company and its products can be found at www.blondertongue.com .
Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes "forward-looking" statements. The forward-looking statements relate to future events regarding such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. In order to comply with the terms of the safe harbor provisions, the Company notes that a variety of factors could cause our actual results and experience to differ materially and adversely from the anticipated results or other expectations expressed in the forward-looking statements. The risks and uncertainties that may affect the operation, performance, development and results of the Company's business include, but are not limited to, those matters discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors," and in the same sections of the Company's subsequently-filed Quarterly Reports on Form 10-Q, as may be further updated by any Current Reports on Form 8-K that we may file. The words "believe," "expect," "anticipate," "project," "target," "intend," "plan," "seek," "estimate," "endeavor," "should," "could," "may" and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, anticipated growth trends in the Company's business and other characterizations of future events or circumstances are forward-looking statements, including statements regarding the Company's ability to continue as a going concern and the Company's ability to maintain the listing of its shares on the NYSE American. Readers also should carefully review the risk factors included in other documents the Company files from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, or, in the case of other documents referred to herein, the dates of those documents. The Company undertakes no obligation to publicly revise or update these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as may be required under applicable law. The Company's actual results may differ from the anticipated results or other expectations expressed in these forward-looking statements.
Contacts
Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000
Ted Grauch
Chief Executive Officer
ted@blondertongue.com
(732) 679-4000
Press Contacts:
Bob Gold
Bob Gold & Associates
bob@bobgoldpr.com
(office) 310-320-2010
Blonder Tongue Laboratories, Inc.
Condensed Consolidated Summary of Operating Results
(unaudited, in thousands, except per share data)
Three months ended | Six months ended | |||
June 30, | June 30, | |||
2021 | 2020 | 2021 | 2020 | |
| Net sales | $4,338 | $3,831 | $7,589 | $7,881 |
| Gross profit | 1,605 | 1,235 | 2,990 | 1,788 |
| Loss from operations | (617) | (1,108) | (1,480) | (3,127) |
| Net income (loss) | $1,626 | $(1,194) | $1,212 | $(3,274) |
| Basic net income (loss) per share | $0.14 | $(0.12) | $0.10 | $(0.34) |
| Diluted net income (loss) per share | $0.11 | $(0.12) | $0.08 | $(0.34) |
| Basic weighted average shares outstanding | 11,984 | 9,766 | 11,818 | 9,766 |
| Diluted weighted average shares outstanding | 15,254 | 9,766 | 15,186 | 9,766 |
Blonder Tongue Laboratories, Inc
Condensed Consolidated Summary Balance Sheets
(in thousands)
(unaudited) | ||
June 30, 2021 | December 31, 2020 | |
Current assets | $7,113 | $6,104 |
Property, plant and equipment, net | 648 | 429 |
Total assets | 11,908 | 11,130 |
Current liabilities | 5,515 | 5,534 |
Long-term liabilities | 2,903 | 4,359 |
Stockholders' equity | 3,490 | 1,237 |
Total liabilities and stockholders' equity | $11,908 | $11,130 |
SOURCE: Blonder Tongue Laboratories, Inc.
View source version on accesswire.com:
https://www.accesswire.com/659422/Blonder-Tongue-Announces-Second-Quarter-and-Six-Months-2021-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
